Figueroa BE, López ZLD, Navarrete FG

Language: Spanish
References: 18
Page: 128-133
PDF size: 310.40 Kb.

ABSTRACT

Kaposi’s sarcoma is a rare multifocal tumor, caused by multiple cell types, mostly endothelial cells, which presents cutaneous and extracutaneous manifestations. At present, been associated with the presence of herpes virus 8 (hv-8), which through various carcinogenic mechanisms, induce mutation and disorderly proliferation of endothelial cells, thereby generating the clinical picture, which can present four Kaposi’s sarcoma nosological varieties: classic, endemic, epidemic (associated with hiv) and iatrogenic. The diagnosis is made by clinical suspicion and the corresponding histopathology. Treatment usually goes hand to hand with clinical presentation, bodily area affected, visceral involvement and associated functional disorders.

REFERENCES

1. López L, Olguín G, González K y Ramos A, Sarcoma de Kaposi clásico. Comunicación de dos casos y breve revisión del tema, Dermatol Rev Mex 2005; 49:265-9.

2. Rojo A, Sarcoma de Kaposi: revisión de la literatura e ilustración de un caso, Act Med Gpo Ángeles 2013; 11(1):23-31.

3. Schwartz R, Micalli G, Nasca M y Scuderi L, Kaposi sarcoma: a continuing conundrum, J Am Acad Dermatol 2008; 59(2):179-206.

4. Osterrieder N, Wallaschek N y Kaufer B, Herpesvirus genome integration into telomeric repeats of host cell chromosomes, Annu Rev Virol 2014; 1:215-35.

5. Cai Q, Verma S, Lu J y Robertson E, Molecular biology of Kaposi’s sarcoma-associated herpesvirus and related oncogénesis, Advances in Virus Research 2010; 78:87-142.

6. Hensler H, Tomaszewski M, Rappocciolo G, Rinaldo C y Jenkins F, Human herpesvirus 8 glycoprotein b bins the entry receptor dc-sign, Virus Research 2014; 190:97-103.

7. Mettenleiter T, Klupp B y Granzow H, Herpesvirus assembly: an update, Virus Research 2009; 143:222-34.

8. Giffin L y Damania B, kshv: pathways to tumorigenesis and persistent infection, Advances in Virus Research 2014; 88:111-59.

9. Muralidhar S, Veytsmann G, Chandran B, Ablashi D, Doniger J y Rosenthal L, Characterization of the human herpesvirus 8 (Kaposi’s sarcoma- associated herpesvirus) oncogene, Kaposin (orf k12), J Clin Virol 2000; 16:203-13.

10. Zong J, Ciufo D, Viscidi R, Alagiozoglou L, Tyring S, Rady P, Orestein J, Boto W, Kalumbuja H, Romano N, Melbye M, Kang G, Boshoff y Hayward G, Genotypic analysis at multiple loci across Kaposi’s sarcoma herpes virus (kshv) dna molecules: clustering patterns, novel variants and chimerism, J Clin Virol 2002; 23:119-48.

11. Lebbé C y Kérob D, Maladie de Kaposi, Encycl Méd Chir, París, Elsevier sas, Dermatologie 2003, 98-655-A-10:12.

12. Martínez M, Pérez L, Escario E y Ribera P, Sarcoma de Kaposi asociado al tratamiento con infliximab, J Am Acad Dermatol 2009; 462-464.

13. Toschi E, Sgadari C, Monini P, Barillari G, Bacigalupo I, Palladino C et al., Treatment of Kaposis sarcoma: an update, Anti-Cancer Drugs 2002; 13:977-87.

14. Guedes F, Andrade H, Fernandes E, Tuon F, Brasil R, Pagliari C y Duarte M, The effects of human herpesvirus 8 infection and interferon-c response in cutaneous lesions of Kaposi sarcoma differ among human immunodeficiency virus-infected and uninfected individuals, Brit J Dermatol 2008; 159:839-46.

15. Requena L y Requena C, Histopatología de las infecciones víricas cutáneas más frecuentes, Acts Dermosifiliogr 2010; 101(3):201-16.

16. Mckee P, McKee’s pathology of the skin with clinical correlations, 4ª ed., Nueva York, Elsevier Saunders 2012: 1729-35.

17. Elder D, Histopatología de la piel de Lever, t. 2, 11ª ed., Amolca 2017: 1275-82.

18. Weedon D, Patología de piel, Marban 2002: 839-843.